MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Advances in chemotherapy of ovarian patients

Back to overy Blogs list Cancer blog  


Subscribe To Overy RSS Feed  RSS content feed What is RSS feed?

Advances in chemotherapy of ovarian patients




Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovary cancer patients who no longer respond to conventional chemotherapy.

A scientific paper that would be reported in the recent issue of the journal Gynecologic Oncology describes how the inhibition of a protein, CHEK1, appears to be an effective element to incorporate into therapies for women with ovary cancer.

The research led by TGen's Dr. David Azorsa, a Senior Investigator, and Dr. Shilpi Arora, a Staff Scientist, observed that inhibiting CHEK1 by a small molecule known as PD 407824, enabled ovary cancer cells to be attacked again by cisplatin, a widely used platinum-based chemotherapy drug for women with ovary cancer.



Advances in chemotherapy of ovarian patients

"PD 407824 is only available for laboratory research, but other drugs inhibiting CHEK1 are already used to treat patients in the clinic," said Dr. Raoul Tibes, one of the paper's senior a co-authors and an Associate Investigator in TGen's Clinical Translational Research Division.

The prognosis remains poor for patients with ovary cancer, which kills nearly 14,600 women in the U.S. annually. The standard therapy for cancer of the ovaries, which produce human egg cells, is surgical removal of the cancer, followed by chemotherapy.

The TGen team proved their method in the research laboratory, which is very encouraging, considering that the use of protein inhibitors in combination with cisplatin, is also proving to be effective in clinical trials with cancer patients.

"The clinical relevance is high, as such novel molecular concepts inhibiting the repair of cancer cells after therapy with chemotherapies are in development for a number of different cancers," said Dr. Tibes, a medical oncologist who treats patients with advanced cancers at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

"We actually have similar drug combinations that go after preventing cancer cells to repair themselves, in the clinic already, and we have seen early exciting results. Patients whose tumors had stopped responding to conventional chemotherapy have been made sensitive again, meaning some of these patients responded again to the chemotherapy. The importance of the paper is that it provides evidence that combinations of cisplatin and CHEK1 inhibitors appears to be worthwhile pursuing in patients with ovary cancer," said Dr. Tibes.

TCRS is a partnership between TGen and Scottsdale Healthcare that enables laboratory discoveries to be quickly translated into effective therapies for patients at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

For this research, TGen researchers used cutting-edge technology to screen 572 kinases, the body's protein enzymes that affect how cells function. They discovered 55 siRNAs strands of RNA molecules that affect the expression of genes that to some degree enabled cisplatin to slow the growth of cancer cells.

As per the paper, one of those small molecule inhibitors, PD 407824, was particularly effective in sensitizing ovary cancer cells, SKOV3 and OVCAR3, to the growth inhibiting effects of cisplatin. PD 407824 and SB 218078 were the two small molecule inhibitors to CHEK1, that were found to sensitize pancreas cancer cells to the chemotherapy drug gemcitabine, as per a paper published by the same group last year in the Journal of Translational Medicine.

"Our new data provide kinase targets that could be exploited to design better therapeutics for ovary cancer patients," said Dr. David Azorsa, Head of TGen's Biological Therapeutics Lab and the senior author of the paper published in Gynecologic Oncology
In addition, Shilpi Arora, a TGen Staff Scientist and the paper's main author, said this data, "also demonstrate the effectiveness of high-throughput RNAi screening as a tool for identifying sensitizing targets to known and established chemotherapeutic agents".


Posted by: Joslyn    Source




Did you know?
Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovary cancer patients who no longer respond to conventional chemotherapy. A scientific paper that would be reported in the recent issue of the journal Gynecologic Oncology describes how the inhibition of a protein, CHEK1, appears to be an effective element to incorporate into therapies for women with ovary cancer.

Medicineworld.org: Advances in chemotherapy of ovarian patients

Ectopic pregnancy| Hyperemesis gravidarum vomiting of pregnancy| Obgyn| Menopause symptoms| Pre eclampsia| Seizures in pregnancy| Spontaneous abortion miscarriage| Symptoms of pregnancy| Ovariancancer| Ovarian cancer statistics| Risk factors for ovarian cancer| Role of radiation therapy in the treatment of ovarian cancer| Role of screening in ovarian cancer| Staging of ovarian cancer| Symptoms of ovarian cancer| Treatment of advanced stage ovarian cancer| Treatment of early stage ovarian cancer| Treatment of ovarian cancer| Treatment of recurrent ovarian cancer| What causes ovarian cancer| Who is more prone to ovarian cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.